SEC Form 4 · accession 0001562180-18-003834
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Sandor
Officer — Chief Medical Officer
Period of report
Sep 4, 2018
Accepted (ET)
Sep 5, 2018 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 4, 2018 | S | 9,687 | $15.375 | D | 210,086 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $15.37 to $15.38. Details of actual prices for shares sold are available from the Issuer upon request.